Patent Grant
11389614
The field of this invention relates to oxygen concentrators. In particular, the invention relates to wearable oxygen concentration systems utilizing vacuum swing adsorption for creating an oxygen stream for ambulatory respiratory patients.
There is a need for home and ambulatory oxygen systems for use by patients. Supplemental oxygen is required for patients exhibiting symptoms from certain diseases and lung disorders; for example, pulmonary fibrosis, sarcoidosis, or occupational lung disease. For such patients, oxygen therapy is an increasingly beneficial prescription to help the patients live normal and productive lives. While not a cure for lung disease, prescriptive supplemental oxygen increases blood oxygenation, which reverses hypoxemia. Oxygen prescriptions prevent long-term effects of oxygen deficiency on organ systems, the heart, brain and kidneys. Oxygen treatment is also prescribed for Chronic Obstructive Pulmonary Disease (COPD), heart disease, AIDS, asthma, and emphysema.
Currently, supplemental medical oxygen for therapy is provided to a patient from high pressure gas cylinders; cryogenic liquid in vacuum-insulated containers or thermos bottles commonly called “dewars”, and oxygen concentrators. Some patients require in-home oxygen only, while others require in-home as well as ambulatory oxygen depending on the prescription. The three systems are all used for in-home use. However, oxygen concentrators provide a special beneficial advantage because they do not require refilling of dewars or exchange of empty cylinders with full ones. Home oxygen concentrators, however, do have drawbacks. They consume relatively large amounts of electricity; are relatively large and heavy; emit excessive heat and are relatively noisy.
There has been a need for an improved portable device for supplying oxygen to a patient. Only small high pressure gas bottles and small liquid dewars are truly portable enough to be used for ambulatory needs. Either system may be used for both in-home and ambulatory use. A patient using a stationary oxygen system at home (or even a portable system which cannot be readily transported), who travels must opt for small cylinders towed in a wheeled stroller or for portable containers that they carry, typically on a shoulder sling. Both of these options have significant drawbacks.
A major drawback of the cylinder option is that small cylinders only provide oxygen for a short duration. Moreover, these cylinders are maintained at a high pressure, and thus their use is restricted due to safety considerations. Another drawback of the cylinders is the refill requirement after depletion of the contents of the cylinder. Empty cylinders must be refilled at specialized facilities, or in the patient's home using a commercial oxygen concentrator which extracts oxygen from the air. The latter option requires an on-site compressor to boost the output pressure of the concentrator to meet cylinder refill pressure requirements. Filling of cylinders with oxygen in the home is potentially dangerous due to the physics involved with compressing gas. Another detriment to cylinder usage is fire hazards associated with storage of large volumes of oxygen in the home environment.
Convenience and safety issues are not the only drawbacks associated with the use of cylinders. Another drawback is the cost associated with cylinders. Cylinders require special care, and specialized materials are required for high pressure oxygen compatibility, which in turn drives up the cost of cylinder-based systems.
The liquid oxygen storage system also has drawbacks. The primary drawback is the requirement of a base reservoir which necessitates refilling once a week or more from an outside source. Liquid oxygen is transferred from the base unit to a portable dewar, which is used by an ambulatory patient. However, there is substantial waste, as a certain amount of oxygen is lost during the transfer to the portable containers and from evaporation. Up to twenty percent of the contents of the base cylinder is lost in the course of two weeks because of losses in transfers and normal evaporation. Even without withdrawal by the patient, the base reservoir will typically boil dry over a period of one to two months.
The aforementioned systems all require a refilling station. When the patient is out in public, such stations are not readily available. Upon running low (or out) of oxygen, the patient must return home to a specified place that can refill the system. Such a requirement detracts from the ambulatory usefulness of the systems.
The industry has developed a set of recommendations for systems targeted to provide portable oxygen for ambulatory patients. The Fifth Oxygen Consensus Conference set forth the following standards for long-term oxygen therapy ambulatory equipment: 1) equipment must weigh less than 10 lbs., 2) equipment must provide the equivalent of 2 liter/min of continuous flow O2, and 3) the flow rate must be maintained for four hours or more. Thus, ambulatory equipment, or personal oxygen systems (POS), are to be inconspicuous to the public as well as unrestricting to the patient. Cylinders and other liquid oxygen systems tend to be bulky, which interferes with normal daily activities. Similarly, cylinders and liquid oxygen systems are difficult to conceal from public view. Ideally, a POS is small, lightweight, quiet, and flexible which allows the device to be concealed from the public. The present invention, whereby oxygen rich gas is provided to a patient from a wearable oxygen concentrator, meets and exceeds these standards.
A removable gas separation cartridge includes a housing having an inlet port, an outlet port, and a bed of adsorbent material. The cartridge is removable from an oxygen concentrator which separates oxygen from ambient air by using an absorption process.
The current invention relates to separation of gases using vacuum swing adsorption. Specifically, disclosed is an oxygen concentrator for a patient who requires a source of oxygen. The present invention is further explained with reference to the drawn figures in which like structures are referred to by like numerals throughout the several views.
Overview—Oxygen Concentrator 100 (
Oxygen delivery tube 102 is a polymer tube or similar oxidation resistant structure, which extends from oxygen concentrator 100 to the nose, mouth, or port into the upper airway of patient P. Tube 102 allows delivery of oxygen to patient P for inhalation. In
Power module 106 provides the necessary power to operate the systems of oxygen concentrator 100. In the embodiment illustrated, power module 106 contains replaceable power pack 108. Reservoir module 110 stores oxygen rich gas that has been separated from ambient air by cartridge module 116. Control module 112 pilots and regulates the interaction of the power module 106, reservoir module 110, and separation cartridge module 116 of oxygen concentrator 100. User interface 114 on control module 112 is a console which allows patient P to adjust and monitor oxygen concentrator 100.
Oxygen Concentrator 100 System Components and Connections (
As shown in
Control module 112 houses main valve 140, drive reducer 142, vacuum pump 144, drive 146, electric control module (ECM) 148, breakthrough flow sensor 150, valve position sensor 152, and contains user interface 114. Main valve 140 is pneumatically connected to adsorbent columns 130a-130c, as well as inlet filter 136 via inlet line 168, vacuum pump 144 via vacuum inlet line 170, product control pump 154 via vacuum line 172 and product gas line 174, and main reservoir 158 via product gas line 176. Valve 140 is actuated by drive 146 through a motor speed reducer 142. Also, valve 140 connects to breakthrough flow sensor 150 and valve position sensor 152 which send electrical inputs 178 and 180 to ECM 148.
ECM 148 is a logic control, such as a PLC (programmable logic controller), microprocessor, or similar structure which controls operation of oxygen concentrator 100. ECM 148 contains the set of inputs and outputs associated with the modules for regulating oxygen concentrator 100. ECM 148 also receives control setting inputs 182 and 184 from user interface 114, and docking station 122, respectively, power pack management input 186 from power pack 108, reservoir pressure input 188 from pressure sensor 159 in main reservoir 158, and nasal pressure input 190 from dispensing valve 160. ECM 148 provides interface output 192 to the user interface 114, interface output 194 to docking station 122, power management output 196 to power pack 108, dispensing valve time open output 198 to dispensing valve 160, and motor drive output 200 to drive 146.
User interface 114 contains physical controls such as dials, toggle switches, push button switches, and similar controls, for operating oxygen concentrator 100. The physical controls provide electrical control settings to ECM 148. ECM 148 reads these settings as inputs 182 and provides output 192 to the user interface 114. The status is converted from electric signals to physical output by indicator lights, status display, and similar structures of user interface 114.
Power pack management input 186 and output 196 control the charge and discharge of voltage from power pack 108 to drive 146 via ECM 148. Drive 146 will activate vacuum pump 144, valve 140 through drive speed reducer 142, and any other systems requiring power. Power pack management output 196 will also supply power to indicator lights, status display, audible alarm (if included), and other passive electrical system requirements on user interface 114 through ECM 148.
ECM 148 controls and coordinates the steps of the vacuum swing adsorption cycle through its inputs and outputs. In one embodiment, breakthrough flow sensor 150 provides an input 178 into ECM 148 by measuring air flow rates. The position of valve 140 is detected by valve position sensor 152 to produce input 180. Reservoir 158 contains a sensor to produce reservoir pressure input 188. Dispensing valve 160 also contains a pressure sensor which provides nasal pressure input 190 in response to differential pressure. ECM 148 reads these inputs to control the cycle by changing outputs, such as motor drive output 200 for drive 146. Drive 146 propels vacuum pump 144. Vacuum pump 144 creates a vacuum that is communicated to valve 140 through vacuum input line 170, while dispelling nitrogen rich gas as exhaust 177. Another output 198 controls the time that dispensing valve 160 is open. In this embodiment, the inputs and outputs are connected to a PLC within ECM 148 which is programmed to control the cycle of oxygen concentrator 100.
Contained within reservoir module 110 is an oxygen-rich gas accumulator comprising reservoir 158, check valve 156, product control pump 154, and check valve 153. Reservoir 158 receives oxygen-rich gas produced by oxygen concentrator 100 and stores it at a low pressure above ambient until it is required for use. A portion of the stored oxygen-rich gas is delivered back to valve 140 by product gas line 176 for use in ordering the nitrogen content in adsorbent columns 130a-130c by moving much of the residual nitrogen held after evacuation near the outlets 134a-134c toward inlets 132a-132c of the columns 130a-130c. Reservoir 158 is in communication with dispensing valve 160 through product gas line 202. Check valve 156 opens to allow oxygen into reservoir 158 and closes to prevent backflow of oxygen upon reaching the desired pressure in reservoir 158.
Product control pump 154 is driven by vacuum provided by the vacuum pump 144 through valve 140 via vacuum line 172. Product line 174 is in communication from separation cartridge module 116 to check valve 153, which opens to allow product control pump 154 to transport separated oxygen-rich gas to reservoir 158. Product control pump 154 delivers the product gas to main reservoir 158 through check valve 156.
Dispensing valve 160 and power pack 108 are contained within power module 106. Dispensing valve 160 is used to feed the flow of oxygen-rich gas to the patient P by delivery of the product gas through final product gas line 205 to product final filter 138. The product gas is obtained from the main reservoir 158 through product gas line 202. Power pack 108 provides the power supply for oxygen concentrator 100 as previously described. Power pack 108 is rechargeable through docking station 122 as represented by power connection 204.
Vacuum Swing Adsorption (VSA) Process-Overview
Oxygen concentrator 100 operates using a vacuum swing adsorption process, which involves a series of cycles that include a feed step or phase, an evacuation step or phase, and a repressurization step or phase. Each of these three phases takes place in one of the three columns 130a-130c at any given time. Each column 130a-130c is in a different phase. For purposes of explanation, the VSA process will be described in reference to A column 130″, which is representative of each of the three columns 130a-130c.
In the feed phase, a gas stream of ambient air 162 enters inlet end 132 of column 130 while product gas containing concentrated oxygen is delivered from outlet end 134 of column 130. The slight vacuum in column 130 draws air 162 into column 130 and through an adsorbent material (typically a zeolite) which preferentially retains specific components of air (nitrogen), allowing the desired product (oxygen) to pass through. A mass transfer zone (MTZ), which is a small region in which nitrogen is being adsorbed, is passing through the adsorbent material. The MTZ divides the column 130 into two segments: a nitrogen-rich segment where the MTZ has passed through, and an oxygen-rich segment ahead of the moving MTZ. The MTZ forms at the inlet 132 at the start of the process and gradually moves through the column to the outlet 134 as the process proceeds. Outlet end 134 of column 130 is connected to main reservoir 158 through main valve 140, check valve 153, and product control pump 154, so that oxygen-rich product gas from column 130 is pumped into reservoir 158.
In the evacuation phase, column 130 is brought to a stronger vacuum by vacuum pump 144, causing the adsorbed component, i.e. nitrogen, to be desorbed. The nitrogen is evacuated from column 130 through main valve 140, and is discharged by vacuum pump 144 as waste exhaust 177.
In the repressurization phase, the previously evacuated column 130 is returned to near 1 atm. Ambient air 162 enters column 130 through inlet end 132, and recycled product gas from product line 176 enters column 130 through outlet end 134. The gases replace the vacuum that was previously drawn in column 130 during the evacuation phase. Just prior to column 130 reaching about 1 atm, the repressurization phase ends and the feed phase of the cycle begins again.
This constitutes the general principles of vacuum swing adsorption (VSA) for gas separation. All phases can be accomplished with a single column, or with a plurality of columns. If a plurality of columns are used, it is preferable to have a multiple of three (illustrated as 130a-130c in
The Feed Phase—Breakthrough Detection
During the feed phase of the separation cycle, the position of the MTZ within adsorbent column 130 is monitored, determined, and beneficially used to control the termination of the feed phase. The control results in improvements in product purity and recovery with concomitant decrease in energy consumed, as well as system size and system weight for a given volume of product produced.
Breakthrough is defined as the point when the MTZ reaches outlet 134 of adsorbent column 130. At this point, feed gas begins to flow into the separated product gas stream. This is undesirable because the purity of the product stream is reduced by the feed stream gas if the feed is allowed to continue past this point. Conversely, if the feed phase is terminated before the MTZ nears outlet 134 of column 130, product recovery will be reduced because product gas contained in column 130 between the MTZ and outlet 134 of column 130 will be subjected to the evacuation phase that follows the feed phase in the separation cycle, and much of this remaining product gas will be lost with the desorbed gas in the waste stream.
For a particular column geometry, temperature, adsorbent type and condition, and cycle vacuum levels, there is an optimal time during the feed phase of the cycle to terminate the feed—before purity requirements are compromised, but after the maximum possible product has been recovered from column 130. This optimal time is determined by the detection of the passage of the mass transfer zone through a specific position relative to outlet end 134 of column 130.
For some combinations of system variables, the optimum feed termination time corresponds to the beginning of breakthrough when the leading edge of the MTZ has just reached outlet end 134 of column 130. This event can be detected by monitoring either or both of the gas flow rates at inlet 132 or outlet 134 to column 130. Before breakthrough, the outlet flow rate is less than the inlet flow rate by an amount equal to the rate of nitrogen gas adsorption of column 130 from the feed gas flow. After breakthrough, column 130 is no longer adsorbing nitrogen from the feed gas, so the inflow and outflow rates of column 130 become equal. Any method of measuring gas flow rates to determine the point in time when these flow rates begin the transition toward equality can be used to detect this beginning of breakthrough.
It has been determined that if the inflow rate of air to column 130 is maintained constant, a simple detection of a significant rise in slope of the outflow rate marks breakthrough. Conversely, if the outflow rate is held fairly steady, then a falling slope of the inflow rate marks the breakthrough. Monitoring the ratio of flow for the inlet and outlet and detecting a significant change in the ratio of flows toward a ratio of 1:1 can mark breakthrough in systems where inflow or outflow may not be steady enough to detect breakthrough by monitoring just one of the flow rates.
For other combinations of system variables, the optimum feed termination time may correspond to the MTZ position prior to breakthrough. In these cases, it is beneficial for a specific amount of product to be intentionally left in column 130 at the end of a feed phase. Detecting the position of the MTZ before breakthrough can be accomplished by additional methods.
One method used determines the volume of gas passed into or out of adsorbent column 130 up to the point of breakthrough by integrating the flow rate during the time interval between an initial feed and breakthrough while using some breakthrough detection method as previously described. Volume of flow may also be directly measured by physical equivalent methods using displacements of known volumes. Once the volume of gas that passes the column up to the point of breakthrough is determined, the volume of gas flow can be monitored during subsequent feed phases and the feed terminated when the volume reaches a specific value less than that for breakthrough. At any time during the feed phase, the volume of gas passed through column 130 since the beginning of feed divided by the volume of gas at breakthrough will be the same ratio as the position of the mass transfer zone divided by the length of column 130 (assuming a constant cross sectional area along the length). Using this relationship, the position of the MTZ within column 130 can be adequately determined during the feed phase.
The components of oxygen concentrator 100 as previously described are used to complete the cyclical phases of VSA to separate gases. The feed phase operates at a slight vacuum just below ambient (in the range of 0.9 to 1 atm). This provides just enough driving force to pull ambient air 162 into adsorbent column 130 through inlet filter 136. The vacuum is caused by product control pump 154, which is driven by the vacuum drawn by vacuum pump 144. Product control pump 154 is a piston pump or similar structure that meters a volume of gas. Product control pump 154 connects with a volume much greater than the piston displacement volume, such as main reservoir 158.
The feed phase is allowed to proceed until breakthrough is detected. Up to this point, the outflow gas from adsorbent column 130 has been a high purity oxygen/argon, low percent nitrogen mixture. The MTZ position is controlled to minimize nitrogen into the product gas mixture. The MTZ position is monitored by breakthrough flow sensor 150, which detects a large increase in flow rate associated with breakthrough when the nitrogen no longer is preferentially adsorbed by adsorbent column 130. Breakthrough flow sensor is located near the column inlet 132, column outlet 134, or similar place where the flow rate being measured is accessible. When the increase MTZ flow is detected, a signal is sent to ECM 148, which also receives valve position signal 180 from the valve position sensor 152. The ECM 148 compares the timing of the MTZ breakthrough signal and the valve position signal and makes a minor adjustment to motor speed 200 based on lead, lag, or on-time status to keep the breakthrough time near the end of each feed phase. Alternately, ECM 148 receives a signal from breakthrough flow sensor 150 and immediately terminates the current feed phase in column 130 by signaling valve 140 to rotate to start the next phase. In yet another embodiment, the separation system contains a shut off valve that is signaled to close the feed of ambient air 162 into column 130, or the delivery of product gas from the column upon breakthrough detection.
In another embodiment, the method for determining the position of the mass transfer zone prior to breakthrough is accomplished by placing a small amount of non-adsorbing material within adsorbent column 130 at a particular position. When the mass transfer zone passes through this position, a flow change is detectable as the adsorption of gas is briefly interrupted by the non-adsorbing segment of column 130. The resulting flow change is detectable using the same methods for breakthrough detection previously described.
With larger columns and slower feed phases, the position of the mass transfer zone has been established by measuring temperature rise at positions of interest within column 130. Significant temperature increases result from the heat of adsorption at the MTZ and can be detected by thermistors or similar devices placed within column 130.
The Evacuation Phase
The evacuation phase brings the gas in adsorbent column 130 that was just in the feed phase to a vacuum state. At the end of the feed phase, the adsorbent column 130 is in equilibrium with the air infeed mixture near 1 atm from column inlet 132 up to the MTZ. Hence, if the ending position of the MTZ is established, and the nitrogen, oxygen, and argon isotherms for the chosen adsorbent mass are known, then the quantity of these gases present in adsorbent column 130 at the end of each feed phase is known. Vacuum pump 144 draws a vacuum on adsorbent column 130. This vacuum level is determined and set to a state that will remove a large portion of the gas left in column 130. In one embodiment, this is 0.2 to 0.3 atm. By percentage, the vast majority of gas discharged is nitrogen. The evacuated gas is discharged as waste from exhaust 177 of vacuum pump 144. The preferred embodiment uses a fixed displacement type of vacuum pump 144. During each evacuation phase, the adsorbed gas in column 130 is expanded into a much larger volume made up of the column volume plus the fixed displacement volume of pump 144.
The evacuate phase creates a self regulating effect that compensates for reductions in the amount of nitrogen adsorbed by adsorbent column 130 as the adsorbent degrades (ages). If the adsorbent loses efficiency, less nitrogen will be present in column 130 at the end of the phase, but the volume of the pump that the nitrogen expands into remains the same. A stronger vacuum will result that will remove more nitrogen and therefore allow more air to be fed during the next feed phase. A more constant breakthrough time results and provides a more robust product cycle.
The evacuation is provided by vacuum pump 144, which is controlled and activated by drive 146. The volume removed for each cycle of the vacuum pump 144 will remain constant, but the motor drive output 200 will be controlled by the rate of product gas used by patient P. The amount of oxygen used by patient P depends on the patient P=s on-demand respiratory rate, which is sensed by the device and from a variable position switch which sends an input 192 from user interface 114 to ECM 148, which in turn provides motor drive output 200 to drive 146. This determines the speed of each successive phase and, therefore, the oxygen production rate.
In one embodiment, a purge is applied at the very end of an evacuation phase. While still in the evacuation phase, a purge of product gas (mostly oxygen) introduced through outlet 134 effectively drives out a portion of nitrogen in column 130 through inlet 132. Adding the purge gas of high purity oxygen/argon through outlet 134 desorbs more nitrogen from outlet 134 of column 130, and pushes the nitrogen toward inlet 132 of adsorbent column 130 and creates an ordering of the gases. The purge volume is a function of vacuum level and adsorbent characteristics. A purge portion of the evacuation phase is not a necessary phase for a functioning device, but allows high oxygen purity to be maintained with weaker vacuum levels.
The Repressurization Phase
The repressurization phase brings adsorbent column 130 (just previously evacuated and purged) up to the feed pressure. In one embodiment, the gas used for repressurization is from both the infeed ambient air 162 and a counter stream from the (oxygen-rich) product gas line 176 from the main reservoir 158. Alternately, the repressurization of product gas can be accomplished through valve design negating the need for a separate line. The product gas is dispensed from a stream of product gas from the adsorbent column that is in the feed phase through a vacuum break valve used during repressurization. Repressurization with product gas can be done before, simultaneously, or after partial pressurization with ambient air. Repressurization with product gas is done at the opposite end of column 130 as repressurization with ambient air 162.
The effect of adding the repressurization gas of high purity oxygen/argon through outlet 134 creates a cleaning zone at outlet 134 of adsorbent column 130 where, during the feed phase that follows next, any stray nitrogen can be preferentially adsorbed and not discharged as product gas. This improves the ordering of gases in the adsorbent column 130. By repeating this phase during successive cycles, the purity will continue to increase in the product output. Weaker vacuums require more oxygen volume returned to column 130 during repressurization if high purity is desired. That is, a stronger vacuum must be drawn on the column 130 to effectuate the same purity of oxygen absent the use of oxygen-rich gas as a back flush for repressurization at the outlet 134 of column 130. At the end of repressurization, the feed phase will proceed.
Valve 140 Timing (
The VSA cycle comprises three phases: evacuation, repressurization, and feed, which occur sequentially in each column 130a-130c. For clarity, only column 130a will be discussed, although each phase is performed (at different times during a complete cycle) in each of columns 130a-130c.
Starting with the evacuation phase of the cycle, a small amount of oxygen (not illustrated) may flow into outlet 134a of adsorption column 130a to purge adsorption column 130a, while vacuum pump 144 withdraws gas present at inlet 134a of the column, i.e. nitrogen-rich gas.
During the repressurization phase, an amount of previously separated oxygen flows into outlet 134a of adsorption column 130a for a short time, and then air is allowed to enter inlet 132a of column 130a that has been previously evacuated. There may be a slight overlap of the oxygen flow into outlet 134a of adsorption column 130a and the air flow in the opposite direction into inlet 132a. Air freely flows into inlet 132a of adsorption column 130a upon opening of valve 140 as adsorption column 130a has been previously evacuated during the evacuation phase.
During the feed phase, air continues to flow into inlet 132a of adsorption column 130a while oxygen is removed from outlet 134a of column 130a by a pressure differential created by product control pump 154. As the MTZ passes through the adsorption column and reaches a position at or near outlet 134a, vacuum pump 144 will again begin to evacuate adsorbent column 130a and restart with the evacuation phase. In the embodiment illustrated in
While column 130a is in feed phase and column 130b is in the repressurization phase, column 130c is in the evacuation phase. During the evacuation phase, a vacuum is drawn to remove adsorbed gas through inlet 132c, thereby regenerating it for the following feed phase.
In the embodiment shown, each column 130a, 130b, and 130c, is in a different phase of the cycle as one moves vertically down the diagram in
For the next one hundred twenty degrees of rotation of valve 140 (i.e., from 120E to 240E), adsorption column 130a is in the evacuation phase. At this same time, column 130b is in the feed phase, and column 130c is in the repressurization phase. Moving horizontally across the diagram for column 130a, during the final one hundred twenty degrees of rotation of valve 140 (i.e., from 240E to 360E), column 130a is repressurized first using separated gas, and then ambient air. Separated gas and ambient air are introduced to the column 130a through column inlet 132a and column outlet 174a at opposite ends of column 130a. During the final one hundred twenty degrees of rotation (i.e. from 2401 to 3601) of main valve 140, column 130b is in the evacuation phase, and column 130c is in the feed phase. Upon reaching three hundred sixty degrees, valve 140 is back at its starting position (zero degrees), and the cycles for each column 130a-130c restart from the zero degree position.
Oxygen Concentrator 100 Physical Components (
In this embodiment, power pack 108 is a rechargeable battery. Receptacle 210 contains electrical contacts (not illustrated) for connection to power pack 108. Cartridge 206 contains a quick-connect attachment (not illustrated) for inlet lines 164a-164c, outlet lines 166a-166c, inlet air line 168, and final product gas line 205 (not illustrated) within receptacle 208. Also present on cartridge 206 are air inlet ports 135 which receive ambient air 162 for separation. Adsorbent cartridge 206 contains adsorbent material that deteriorates in efficiency as it is used and ages.
Utility tubes 212 run between the adjacent modules and contain either electrical wiring or pneumatic lines, or comprise pneumatic lines and electrical wiring and associated connections. Tubes 212 are constructed to be flexible and bend as belt 104 is manipulated. If the tubes 212 contain electrical lines, the tubes are constructed from a dielectric material to insulate electrical wires, or similar material commonly used in electrical connections. If the tubes 212 comprise pneumatic lines, they may be air tight, small diameter polyvinyl or PVC tubes to connect the various gas input, gas separation, and gas removal systems of the oxygen concentrator 100. Tubes 212 contain openings or connections as required for electrical and pneumatic communication with each module. The back interior surface 211 of belt 104 contains tube pathways 214. Pathways 214 fabricated on the interior surface 211 of belt 104 allow the utility tubes 212 to extend between the modules 106, 110, 112, and 116. Tube pathways 214 create a semi-partitioned area on back interior surface 211 of belt 104 which support tubes 212.
Belt 104 is fabricated to contain apertures 216a-216d which allow modules 106, 110, 112, and 116 to connect utility tubes 212 of belt 104 through sockets 218a-218d. Apertures 216a-216d and sockets 218a-218d are fabricated as part of modules 106, 110, 112, and 116. Serrations 118 can be seen between the upper and lower edges 220 and 222 of belt 104. When fabrication of belt 104 is completed, padding will be inserted between edges 220 and 222, and material will be wrapped around creating serrations 118 and belt segments 120 to complete belt 104 as illustrated in
Each module 106, 110, 112, and 116, comprises a case portion 224, 226, 228, and 230, defining the outer volume of each respectively. Bottom padding 232, 234, 236, and 238, covers the lower base portion of each module 106, 110, 112, and 116, respectively. Similarly, top padding 240 extends around the top perimeter of power module 106, while top padding 242 and 244 covers the top portions of modules 110 and 112. Power pack top padding 246 covers the top portion of power pack 108 and cartridge top padding 248 covers the top of separation cartridge 206. Padding 222-248 is a foam or similar lightweight material that adds protection to the modules as well as acts to reduce vibration of oxygen concentrator 100 felt by patient P. Alternately, oxygen concentrator 100 is enclosed in soft, flexible material to further increase comfort and maintain flexibility. In one embodiment, padding 232-248 is fabricated separately from the modules 106, 110, 112, and 116, power pack 108 and cartridge 206. In assembling the oxygen concentrator 100, padding 232-248 and case portions 224, 226, 228, and 230, are merged and secured either using fasteners, adhesives, or a manufacturing process such as ultrasonic welding.
Case portions 224, 226, 228, and 230, of each of the modules 106, 110, 112, and 116, contain sockets 218a-218d fabricated on the surface that contacts belt 104. Socket 218a-218d for each module is constructed to have support paths 250 for electrical wiring and pneumatic tubing similar to those contained within belt 104 represented by tube pathways 214. Sockets 218a-218d are constructed so that support paths 250 on sockets 218a-218d align with tube pathways 214 in belt 104 when each individual module 106, 110 ,112, and 116, is connected to belt 104. In one embodiment, sockets 218a-218d are constructed to allow each individual module 106, 110, 112, and 116, to snap onto belt 104 or attach in a similar quick connect fashion. Utility tubes 212 comprise quick connects at module apertures 216a-216d. Apertures 216a-216d are openings in the case portions 224, 226, 228, and 230, provided for connection of utility tubes 212 to components contained within each module 106, 110, 112, and 116. This allows for removal of a single module 106, 110, 112, or 116 should a specific component require maintenance or replacement. Sockets 218a-218d are constructed from the same material as the case portions 224, 226, 228, and 230.
Main electrical cable 254 contains a set of electrical wires that carry inputs 178, 180, 182, 188, and 190, outputs 192 and 198, and power lines 186, 198, and 200 shown in
Product gas line 202 connects dispensing valve 160 with reservoir 158 of accumulator 252. Final product gas line 205 connects dispensing valve 160 to product gas outlet port 103 for connection to delivery tube 102 after passing through final filter 136 located in adsorbent cartridge 206 to provide patient P with oxygen rich product gas. Product control pump inlet line 174 extends from main valve 140 to product control pump 154, which pumps separated oxygen rich gas into reservoir 158. Vacuum line 172 connects product control pump 154 through valve 140 to a vacuum drawn by vacuum pump 144, and provides the actuation for product control pump 154. Column inlet lines 164a-164c and column outlet lines 166a-166c connect main valve 140 with column inlet ports 132a-132c and column outlet ports 134a-134c of columns 130a-130c, respectively (not illustrated). Inlet air line 168 transports ambient air 162 from separation cartridge 206 to main valve 140, while vacuum inlet line 170 connects vacuum pump 144 to main valve 140. All lines 164a-164c, 166a-166c, 168, 170, 172, 174, 176, 202, and 205, are pneumatic lines or similar structures that allow for the isolated flow of gases between system components.
Power pack 108 is a lithium based battery pack capable of being recharged in a recharging socket or station that connects to an external power supply. Alternatively, power pack 108 comprises a battery or fuel cell. In one embodiment, power pack 108 is a lithium ion battery pack that is constructed from several interconnected lithium-ion batteries. Oxygen concentrator 100 uses a maximum of fifteen watts of power. This results in a battery weight of less than 0.7 pounds (0.3 kg). In this embodiment, patient P taking twenty breaths per minute at a setting of 2 liters per minute equivalent can use oxygen concentrator 100 for a minimum of four hours on a fully charged battery. Power pack 108 is easily exchanged with another similar battery pack, and can be removed with a simple pulling or tugging motion. In another embodiment (not illustrated), oxygen concentrator 100 contains a jack for receiving a power cord which can then be plugged into either a 110 volt wall outlet or a 12 volt power supply system (such as a car utility plug) so that power pack 108 can be charged in place in oxygen concentrator 100.
Power pack life indicator 260 displays the amount of time left that the power pack will operate the oxygen concentrator 100. As illustrated, power pack life indicator 260 is a display, such as a liquid-crystal display (LCD) or light emitting diode (LED) screen, with numeric output of expected life in hours. The LCD or LED screen may also contain a series of bars that act as indicators. Alternately, power pack life indicator 260 is a light or series of lights.
Dispensing valve 160 is contained within power module 106 and is used to feed the flow of oxygen to patient P. Dispensing valve 160 is a valve activated by a change in pressure, such as that caused when a person is inhaling. A sensor in the dispensing valve circuit monitors pressure, and opens dispensing valve 160 when a drop in pressure is sensed. ECM 148 communicates with dispensing valve 160 through input 190 and output 198 (see
Dispensing valve 160 provides for operating oxygen concentrator 100 in one of two possible modes: pulse flow or continuous flow. When patient P is using the oxygen concentrator 100 in the pulse flow mode, dispensing valve 160 will open intermittently in response to inhalation and will stay open for a pulse time according to the setting of the controls as set by patient P. If continuous flow is desired, dispensing valve 160 is maintained at an open or partially opened state. The product is dispensed to patient P though oxygen delivery tube 102 at a continuous rate, typically in the range of 1-1.5 lpm (liters per minute). The pressure difference corresponding to a dispensing orifice in delivery tube 102 will accommodate the flow rate from the reservoir 158.
Product control pump 154 includes piston 262, actuated by spring 264 within pump chamber 265, which pushes separated oxygen-rich product gas into reservoir 158. Check valve 156 opens to allow oxygen into the reservoir 158 and closes to prevent back flow of oxygen-rich gas when the desired pressure in reservoir 158 is attained. The low pressure of reservoir 158 exerts a force on check valve 156 to keep valve 156 closed. Reservoir 158 takes oxygen-rich gas produced by oxygen concentrator 100 and stores it at a low pressure above ambient until the product is required for use by patient P.
Product control pump 154 is driven by vacuum. Product control pump vacuum line 174 is connected to the vacuum drawn by vacuum pump 144 through main valve 140. When a vacuum is drawn, the force draws piston 262 down to compress spring 264 which expands pump chamber 265, and causes check valve 153 to open. Oxygen-rich gas from separation cartridge 206 flows through check valve 153 and enters pump chamber 265 in the volume created by the displacement of piston 262. At the appropriate time in the cycle, valve 140 will interrupt the vacuum to product control pump 154, and spring 264 will force piston 262 upwards. The movement of piston 262 will force oxygen rich gas in pump chamber 265 through check valve 156 and into reservoir 158. At the same time, check valve 153 closes to prevent more gas from entering pump 154. With this embodiment, no additional drive (other than the vacuum to pull piston 262 down and the spring force to move it up) is required for product control pump 154 which adds to the overall efficiency of the system.
In one embodiment, reservoir 158 has a capacity that is about four times larger than the size of the largest pulse provided by oxygen concentrator 100. In one embodiment, extra volume is included to account for separated oxygen used as a back flow in adsorbent columns 130a-130c. Specifically, main storage reservoir 158 for oxygen concentrator 100 can be designed according to the flow rates listed in Table 1. Storage reservoir 158 is 100 cc (cubic centimeters) to 400 cc in volume. Main storage reservoir 158 is maintained at a low pressure to provide delivery of the product gas to patient P through outlet 263 which is connected to final product dispensing line 202. In one embodiment, the pressure is between 1 atm (ambient) and 1.5 atm. Also acceptable are pressures less than eight psi (55,158 Pa), with a pressure of two and one half to five psi (17,236 to 34,473 Pa) preferred. The low pressure of reservoir 158 allows oxygen concentrator 100 to be used in most areas where high pressure oxygen is banned. Also, low pressure requires less energy to fill reservoir 158, which adds to the efficiency of the system by requiring a simpler pressurizing mechanism compared to high pressure systems.
Reservoir 158 contains pressure sensor 159 (such as a piezoresistive or capacitive sensor) that sends reservoir pressure signal 188 to ECM 148 (see
Flow settings are dually controlled by patient P utilizing flow setting switches 270. First, continuous or pulse mode is selected by patient P. In a continuous flow mode, oxygen is dispensed at a continuous flow rate such as one to one and a half liters per minute. If oxygen concentrator 100 is set in a pulse mode for controlling flow, oxygen concentrator 100 utilizes dispensing valve 160 to provide pulse dispensing of product gas. The pulse mode is set to meet patient P=s needs for the equivalent of one to five liters per minute of continuous oxygen flow. In one embodiment, a dial containing settings of one to five is utilized. In the embodiment illustrated in
When the unit is set in pulse mode, product gas is dispensed only at the beginning of inhalation. In one embodiment, product dispensing valve 160 is only opened between zero and 0.4 seconds of the beginning of a breath of patient P. This controls the amount of oxygen removed from reservoir 158. In another embodiment, oxygen concentrator 100 is shut off if no pressure drop is sensed by nasal pressure sensor 190 for a set amount of time, such as two minutes, which in turn closes dispensing valve 160.
Patient P can temporarily increase (or Aboost@) the flow rate of oxygen by actuating boost control switch 272 on user interface 114. When boost switch 272 is activated, oxygen concentrator 100 increases the flow rate of oxygen for a set period of time, such as 10 minutes. After timing out, oxygen concentrator 100 returns to the previous setting. The boost function will not work if oxygen concentrator 100 is already operating at the maximum flow rate.
Indicator light 274 indicates power pack 108 is running low. Indicator light 276 indicates that there is a problem with separation cartridge 206, such as a bad connection with receptacle 208. In one embodiment, oxygen concentrator 100 contains three different colored lights: red, yellow, and green. The green light indicates that there are no problems detected with oxygen concentrator 100. A yellow flashing light or a yellow non-flashing light indicates a condition has been sensed that should be addressed. An example of such a condition is a low battery. A red flashing light indicates that a condition has been detected that requires an immediate response. A red non-flashing light indicates that oxygen concentrator 100 has failed, and has shut down. For example, if oxygen concentrator 100 fails to produce a stream of separated gas of eighty-five percent oxygen, oxygen concentrator 100 will detect this problem via breakthrough flow sensor 150. ECM 148 shuts off main valve 140 so no ambient air 162 is being submitted to the gas separation cartridge 206. Product gas is no longer being supplied to reservoir 158. After a few breaths, reservoir 158 will empty, triggering reservoir pressure sensor output 188 (shown in
Valve 140 is a valve containing a minimum number of ports equal to two times the number of adsorbent beds (columns) in separation cartridge 206. Additionally, main valve 140 contains other ports for the inlet of ambient air 162, vacuum provided by vacuum pump 144, and recycling of product gas used to purge columns 130a-130c during repressurization. In the preferred embodiment, valve 140 is a rotary valve, but may also be a solenoid valve, directional control valve, or series of individual valves in communication with each other and each connected to an adsorbent column 130a-130c.
In an alternate embodiment, drive 146 may contain an independent motor for operating valve 140. If valve 140 is run by an independent motor, that motor is powered by power pack 108 and synchronized with the other motor(s) of drive 146 by ECM 148. As illustrated, drive 146 contains a single motor and valve 140 is connected to a system of gears that comprise drive speed reducer 142. Alternately, drive speed reducer 142 can be any common power transmission components such as pulley and belts, or gears and sprockets.
Column inlet ports 132a-134c are connected to receive either ambient air 162 or vacuum, while outlet ports 134a-134c expel product gas or receive purge gas. This arrangement promotes ordering of gases within the columns 130a-130c by having oxygen rich gas always present at one end of the column. This results in improved efficiency as air flow through the columns 130a-130c creates an oxygen rich zone continuously at one end, which allows the vacuum to evacuate and desorb the previously adsorbed nitrogen where it is contained in the greatest concentration.
Adsorbent material 282a-282c is the same as that previously described. Filters 136 and 138 are constructed of common filtering materials and are used to remove dust and other large particulate matter from the air streams to assure that the flow of oxygen out to patient P is free of such materials. Porous filters 284a-284f are a small section of material commonly used as a particle filter provided at each end of columns 130a-130c. Porous filters 284a-284f act to prevent adsorbent particles from contacting the mechanisms and valving of concentrator 100.
Docking Station 122 (
In one embodiment, docking station 122 comprises indicator lights and control power switch (not illustrated) in addition to status display 288, power pack chargers 124a and 124b, and concentrator dock 126. Indicator lights provide information to patient P utilizing oxygen concentrator 100. Indicator lights will indicate if oxygen concentrator 100 is functioning properly, requires maintenance, or has failed. Control switch is a master switch for supplying or terminating power or controlling the setting of flow for oxygen concentrator 100. Status display 128 is an LED, LCD or similar digital display that can be used to indicate various information to patient P such as time of day, time oxygen concentrator 100 has been docked, time of recharging for the power pack, or similar information.
Docking station 122 also contains power pack chargers 124a and 124b and concentrator dock 126. Docking station 122 contains a power cord (not illustrated) available to plug into a wall socket or a similar power pack. Docking station 122 converts AC power to recharge power pack 108 in power pack chargers 124a and 124b. Power pack chargers 124a and 124b contain contacts that are used to transfer power to power pack 108 while recharging. Alternatively, a power pack 108 placed in charger 124a or 124b is inductively coupled to recharge the power pack 108. Similarly, power is provided to oxygen concentrator 100 itself while on docking station 122, and to recharge of the power pack 108 (see
In one embodiment, docking station 122 performs several functions with oxygen concentrator 100 docked. First, oxygen concentrator 100 is allowed to run without utilizing power pack 108 while it is docked. Second, a boost setting is available to increase the delivery rate of oxygen while oxygen concentrator 100 is docked. Boost switch 272 is located on user interface 114 (See
Oxygen concentrator 100 contains flow setting switch 270 (
Another function of docking station 122 is to provide diagnostic features of the system. Docking station 122 may indicate expected battery life, adsorbent column life, or pump malfunctions through the use of indicator lights, or status display 128, or a combination of both. Alternatively, these items are located on user interface 114, or at a combination of locations of user interface 114 and docking station 122. For example, battery life indicator 142 is located directly on power pack 108 that comprises the battery itself, and battery problem warning light 274 is on user interface 114 also. Similarly, adsorbent cartridge warning light 276 is located on user interface 114, but may also be on either the cartridge module 116 or docking station 122 as well.
Concentrator Efficiency
Oxygen concentrator 100 can produce a stream of product gas containing a range of 85-95 percent oxygen which provides up to 5 liters per minute pulsed equivalent of product gas. By utilizing vacuum swing adsorption, the separation process phases are all performed at less than 1 atm.
Utilizing a vacuum to exhaust unwanted gas from adsorbent columns 130a-130c improves efficiency of the oxygen concentrator 100. Less power is required than pressure swing adsorption (PSA) or vacuum-pressure swing adsorption (VPSA), which results in a smaller battery and thus a lighter weight product. Oxygen concentrator 100 as disclosed weighs less than 3 pounds (1.4 kg) and occupies less than 1 liter of volume. Also, the efficiency of the system allows for oxygen concentrator 100 to operate for at least three hours while producing up to 5 liters per minute pulsed equivalent of product gas without requiring patient P to attend to the unit, e.g. changing the battery. Further, the low energy consumption causes less heat transfer. The product gas is discharged from the separation system at a temperature of ±six degrees Celsius from that of the ambient air. This eliminates the need for heat exchangers which add to the overall weight and reduces system efficiency. The amount of heat generated causes no discomfort to patient P wearing and utilizing the oxygen concentrator 100. Also, upon starting oxygen concentrator 100, the flow of product gas will increase from 21 percent oxygen (ambient) to 85 percent or more oxygen in under two minutes.
Improvements over the prior art are attained by regulating the device to only separate the amount of oxygen needed by patient P at any given time. The prior art separates a flow of oxygen and delivers that rate to patient P as a steady flow. Patient P is only inhaling this oxygen during about ⅓ of the normal breathing cycle. Within the inhalation portion of the breathing cycle, the volume of gas inhaled last stays in the dead space of the airways and is not presented to the alveoli. Therefore if oxygen is dispensed to patient P only during the early part of inhalation, less than ⅓ the steady flow is actually required. Moreover, prior art devices do not adjust the flow based on a patient P=s needs, but operate at the same steady flow. The present concentrator slows down its entire cycle rate producing only the amount of oxygen needed. Thus, oxygen concentrator 100 retains a high oxygen recovery percentage at all product flow rates while minimizing energy consumption and maximizing adsorbent life. Patient P=s actual needs vary with real time changes in activity. This causes a corresponding variation in breathing rate. Oxygen concentrator 100 tracks patient P=s breathing rate and adjusts oxygen separation and delivery rates proportionally. In combination, these two features allow oxygen concentrator 100 to separate oxygen only at the rate it is being consumed, resulting in a reduction in the amount of oxygen needing to be separated for patient P.
Another improvement over the prior art involves reducing the waste of separated oxygen in the various adsorb and desorb cycle phases. This is typically referred to as maximizing product recovery. The primary system components become larger or smaller as the amount of oxygen separated increases or decreases. Therefore, a dramatic reduction in size and weight of the concentrator requires use of as much separated oxygen as possible by delivering it to patient P rather than losing it to the waste stream. The prior art works by using the Skarstrom cycle well known to those skilled in the art.
During one phase of the Skarstrom cycle in PSA or VPSA, air is pumped into one end of a column of adsorbent pressurizing it above atmospheric pressure while oxygen is flowing out of the opposing end. Nitrogen is being adsorbed as the MTZ propagates toward the oxygen outlet end of the column. This phase is terminated before the MTZ breaks through into the oxygen stream so that oxygen purity is not diluted by the nitrogen rich air trailing the MTZ. If it is terminated earlier than necessary to maintain purity there will be substantial separated oxygen left in the column in front of the MTZ that is not passed to the patient. During the next cycle phase the column pressure is reduced to a lower cycle pressure desorbing the nitrogen that was adsorbed during the separation phase and it is passed to the waste stream. Some of the oxygen left in the column at higher pressure will also be passed to the waste stream as gas flows from the column when pressure is reduced. Recovery of separated oxygen can therefore be maximized by stopping the previous separation phase just short of breakthrough, leaving minimal oxygen in the column to be lost to the waste stream during the reduced pressure evacuation phase. The position of the MTZ needs to be accurately known to terminate the separation phase for optimal recovery without compromising purity. This position cannot be accurately estimated because its propagation rate is a function of many variables including product oxygen flow rate, high and low cycle pressures, temperature, adsorbent water content and the amount of other contaminants accumulated in the adsorbent. Prior art systems stop the separation phase well short of breakthrough to encompass worst case operating conditions without sacrificing purity and thereby waste separated oxygen in the evacuation phases during most typical non-worst case operating conditions.
Oxygen concentrator 100 determines the position of the MTZ just prior to breakthrough and terminates the flow from outlet 134 for the remainder of the feed phase or adjusts the motor speed, as previously described. Additional oxygen is left in the column at the end of a feed phase and is wasted during the evacuation phases. This is oxygen adsorbed by the adsorbent combined with oxygen present in the interstitial and dead spaces of the adsorbent and column. All adsorbents used in oxygen separators adsorb nitrogen, and also oxygen to some extent. The adsorbent used in oxygen concentrator 100 presents a very high ratio of adsorbed nitrogen to adsorbed oxygen. As the amount of oxygen adsorbed is minimized through the choice of an adsorbent with a low affinity for oxygen, the amount of adsorbent needed to separate a given amount of nitrogen during a separation phase will decrease as its affinity for nitrogen increases. The less adsorbent needed to adsorb a given amount of nitrogen, the less adsorbent there is to adsorb oxygen and the smaller the column can be with less interstitial and dead space.
For example, a LiLSX adsorbent referred to as Oxysiv MDX from UOP Corporation has a very high ratio of adsorbed nitrogen to adsorbed oxygen in the operating pressure range of oxygen concentrator 100. The Skarstrom cycle of the prior art uses a purge phase in which separated oxygen is fed back into the product end of the column while nitrogen rich gas is passing out of the opposing end of the column into the waste stream as the pressure transitions to the lower cycle pressure. While this purge can enhance product purity, some of the purge oxygen passes all the way through the column and is lost to the waste stream. Oxygen concentrator 100 using VSA achieves a measured 60% oxygen recovery rate, compared to a typical recovery rate of 30% for the prior art utilizing PSA.
Another improvement over the prior art concerns the choice of adsorbent and operating pressure range. The energy required by the separation process directly defines the weight and size of major components such as the battery, motor and gas pump of a concentrator. Minimizing the amount of adsorbent minimizes the amount of energy needed to separate a given amount of oxygen. Each adsorbent has a characteristic pair of isotherms that show the amount of oxygen and nitrogen a given mass of adsorbent will hold at equilibrium over a range of pressures and vacuums for these gasses at a constant temperature. The cycle phases of the system necessarily include the pumping of gas contained in volumes of adsorbent to produce a change in nitrogen partial pressure between a chosen higher pressure and a chosen lower pressure. The pneumatic energy a pump must deliver in the process of cycling a given volume of gas between a higher and a lower level is in direct proportion to the volume of gas pumped multiplied by the difference between the high and low vacuum levels. The isotherms for various adsorbent candidates specify the amount of nitrogen contained in a fixed mass of adsorbent at a fixed temperature as a function of nitrogen partial pressure.
An example of the isotherm for the LiLSX adsorbent Oxysiv MDX along with the isotherm for a typical 13× type adsorbent used in the prior art is shown in
For example, prior art operates between 1 and 3 atmospheres for a 3:1 ratio and a pressure difference between high and low levels of 2 atmospheres. Oxygen concentrator 100 using VSA operates between 0.3 atmospheres and 1 atmosphere. A ratio of about 3.3:1 is achieved with a pressure difference of only 0.7 atmospheres. Operating on this range of the isotherm as seen in
Oxygen concentrator 100 is a quiet device. When oxygen concentrator 100 is running, it produces a noise level in the range of ten to thirty decibels. Further, with the compact size of the parts, vacuum pump 144 is running continuously and there is very little vibration to affect a person using it docked or wearing it as an ambulatory device. The device of the present invention with the described components weighs less than three pounds (1.36 kg). The compact size (less than about 61 cu. in. (1000 cc)) allows for easy portability. Similarly, the small size does not disrupt counter space or storage when used at home. The device does give off some heat, however the outer case is less than 6 degrees Celsius higher than ambient when oxygen concentrator 100 is running on battery power. The device may emit more heat while it is docked and operating on AC power to charge the power pack 108, but is still less than 15 degrees Celsius above ambient.
Based on the foregoing embodiments, the efficiency of the concentrator can be determined. One measure of efficiency is the ratio of oxygen produced to the amount of adsorbent material used to obtain the oxygen, represented by the following:
for the system.
The following flow rates (Qp) were obtained by the above disclosed concentrator:
This results in a range for kilograms of adsorbent material to oxygen flow rate of:
Similarly, flow rates (Qp) were determined for a system that contains three adsorption columns, each column containing 15 cc of adsorbent material. The separation completed in a range of 0.3 atm to 0.95 atm. Values were calculated for breakthrough time, work, battery life, and flow rate. The volume of gas contained in a column at the end of a feed phase was 150 cc. These constants were used to determine the following measures of efficiency:
Work per evacuation cycle or pneumatic power requirements were determined based on the following calculations:
Inserting the above constants and converting to joules (multiply by 100.32 to get L*atm to joules) yields:
W=4.81 joules
Thus, 4.81 joules is required to evacuate the gas which desorbs during the evacuation phase. From experimentation, the following flow rates (LPM is liters per minute) and cycle times were recorded:
From the above, a measure of energy consumed to the flow rate can be made and used as an indicator of the system efficiency:
Another measure of efficiency is the ratio of mass of the power pack (Mpowerpack) compared to the amount of oxygen produced (Qp) over time:
The following constants are used in the calculation: the battery cell is a type 18650 lithium ion battery with 7.4 watts-hrs, measuring 42 g; motor efficiency is 90 percent; and vacuum pump efficiency is 80 percent.
Pneumatic work=6 W/L/min. Thus,
Battery mass compared to energy consumption is:
Total battery mass for the power pack can be determined from this equation. For example, if a patient requires the concentrator to run for four hours at setting of A3″ and takes 20 breaths per minute (the medium flow rate):
The mass of the batteries needed is 0.135 Kg. Assuming each battery cell is 42 g as previously stated, the number of batteries for the power pack can be calculated:
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention. For example, larger flow rates may be achieved by scaling the concentrator components to achieve desired flow rates at the disclosed efficiencies.
This application is a continuation of earlier filed application Ser. No. 14/193,504, filed Feb. 28, 2014, which is a continuation of application Ser. No. 13/795,977, filed Mar. 12, 2013, which is a continuation of application Ser. No. 13/096,362 filed Apr. 28, 2011, which is a continuation of application Ser. No. 11/054,341, filed Feb. 9, 2005. The '504, '977, '362, and '341 Applications are incorporated by reference herein in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3121625 | Broughton | Feb 1964 | A |
| 3236028 | Rutan | Feb 1966 | A |
| 3717974 | Batta | Feb 1973 | A |
| 3880616 | Myers et al. | Apr 1975 | A |
| 3922149 | Ruder et al. | Nov 1975 | A |
| 4169715 | Eriksson | Oct 1979 | A |
| 4194890 | McCombs et al. | Mar 1980 | A |
| 4222750 | Gauthier et al. | Sep 1980 | A |
| 4263018 | McCombs et al. | Apr 1981 | A |
| 4354859 | Keller, II et al. | Oct 1982 | A |
| 4386945 | Gardner | Jun 1983 | A |
| 4448592 | Linde | May 1984 | A |
| 4449990 | Tedford, Jr. | May 1984 | A |
| 4472177 | Sircar | Sep 1984 | A |
| 4491459 | Pinderton | Jan 1985 | A |
| 4502873 | Mottram et al. | Mar 1985 | A |
| 4576616 | Mottram et al. | Mar 1986 | A |
| 4584001 | Dechene | Apr 1986 | A |
| 4627860 | Rowland | Dec 1986 | A |
| 4648395 | Sato et al. | Mar 1987 | A |
| 4648888 | Rowland | Mar 1987 | A |
| 4673415 | Stanford | Jun 1987 | A |
| 4681099 | Sato et al. | Jul 1987 | A |
| 4684377 | Haruna et al. | Aug 1987 | A |
| 4702903 | Keefer | Oct 1987 | A |
| 4801308 | Keefer | Jan 1989 | A |
| 4802899 | Vrana et al. | Feb 1989 | A |
| 4813977 | Schmidt et al. | Mar 1989 | A |
| 4816121 | Keefer | Mar 1989 | A |
| 4826510 | McCombs | May 1989 | A |
| 4880443 | Miller et al. | Nov 1989 | A |
| 4892566 | Bansal et al. | Jan 1990 | A |
| 4925460 | Coe et al. | May 1990 | A |
| 4925464 | Rabenau et al. | May 1990 | A |
| 4948401 | Izumi et al. | Aug 1990 | A |
| 4968329 | Keefer | Nov 1990 | A |
| 4971609 | Pawlos | Nov 1990 | A |
| 4973339 | Bansal | Nov 1990 | A |
| 5002591 | Stanford | Mar 1991 | A |
| 5034023 | Thompson | Jul 1991 | A |
| 5069688 | Wells | Dec 1991 | A |
| 5071449 | Sircar | Dec 1991 | A |
| 5082473 | Keefer | Jan 1992 | A |
| 5084075 | Sircar | Jan 1992 | A |
| 5096469 | Keefer | Mar 1992 | A |
| 5112367 | Hill | May 1992 | A |
| 5114440 | Reiss | May 1992 | A |
| 5169506 | Michaels | Dec 1992 | A |
| 5186793 | Michaels | Feb 1993 | A |
| 5228840 | Swank | Jul 1993 | A |
| 5247826 | Frola et al. | Sep 1993 | A |
| 5256172 | Keefer | Oct 1993 | A |
| 5266102 | Gaffney et al. | Nov 1993 | A |
| 5268021 | Hill et al. | Dec 1993 | A |
| 5268023 | Kimer | Dec 1993 | A |
| 5275642 | Bassine | Jan 1994 | A |
| 5328503 | Kumar et al. | Jul 1994 | A |
| 5330561 | Kumar et al. | Jul 1994 | A |
| 5340381 | Vorih | Aug 1994 | A |
| 5366541 | Hill et al. | Nov 1994 | A |
| 5370112 | Perkins | Dec 1994 | A |
| 5411578 | Watson et al. | May 1995 | A |
| 5415683 | Leavitt | May 1995 | A |
| 5429666 | Agrawal et al. | Jul 1995 | A |
| 5441558 | Lee et al. | Aug 1995 | A |
| RE35099 | Hill | Nov 1995 | E |
| 5469372 | McBrearty et al. | Nov 1995 | A |
| 5474595 | McCombs | Dec 1995 | A |
| 5487775 | LaCava et al. | Jan 1996 | A |
| 5531807 | McCombs | Jul 1996 | A |
| 5540758 | Agrawal et al. | Jul 1996 | A |
| 5565018 | Baksh et al. | Oct 1996 | A |
| 5578115 | Cole | Nov 1996 | A |
| 5593478 | Hill et al. | Jan 1997 | A |
| 5656066 | Reiss et al. | Aug 1997 | A |
| 5656067 | Watson et al. | Aug 1997 | A |
| 5672195 | Moreau et al. | Sep 1997 | A |
| 5711787 | Neill et al. | Jan 1998 | A |
| 5730778 | Hill et al. | Mar 1998 | A |
| 5753010 | Sircar et al. | May 1998 | A |
| 5762686 | Borzio | Jun 1998 | A |
| 5772737 | Andreani et al. | Jun 1998 | A |
| 5779766 | Weigel et al. | Jul 1998 | A |
| 5797979 | Quinn | Aug 1998 | A |
| 5814130 | Lemcoff et al. | Sep 1998 | A |
| 5814131 | Lemcoff et al. | Sep 1998 | A |
| 5820656 | Lemcoff et al. | Oct 1998 | A |
| 5827358 | Kulish et al. | Oct 1998 | A |
| 5858062 | McCulloh et al. | Jan 1999 | A |
| 5871564 | McCombs | Feb 1999 | A |
| 5882380 | Sircar | Mar 1999 | A |
| 5891217 | Lemcoff et al. | Apr 1999 | A |
| 5893275 | Henry | Apr 1999 | A |
| 5893944 | Dong | Apr 1999 | A |
| 5906672 | Michaels et al. | May 1999 | A |
| 5917135 | Michaels et al. | Jun 1999 | A |
| 5928189 | Phillips et al. | Jul 1999 | A |
| 5931159 | Suzuki et al. | Aug 1999 | A |
| 5935297 | Amlinger | Aug 1999 | A |
| 5948142 | Holmes et al. | Sep 1999 | A |
| 5968236 | Bassine | Oct 1999 | A |
| 5979440 | Honkonen et al. | Nov 1999 | A |
| 5985001 | Garrett et al. | Nov 1999 | A |
| 5985113 | Crome et al. | Nov 1999 | A |
| 5988165 | Richet, II et al. | Nov 1999 | A |
| 5997611 | Doong et al. | Dec 1999 | A |
| 5997617 | Czabala et al. | Dec 1999 | A |
| 6010555 | Smolarek et al. | Jan 2000 | A |
| 6017315 | Starr et al. | Jan 2000 | A |
| 6030435 | Monereau et al. | Feb 2000 | A |
| 6033457 | Lawless | Mar 2000 | A |
| 6051050 | Keefer et al. | Apr 2000 | A |
| 6056804 | Keefer et al. | May 2000 | A |
| 6068680 | Kulish et al. | May 2000 | A |
| 6093379 | Golden et al. | Jul 2000 | A |
| 6096115 | Kleinberg et al. | Aug 2000 | A |
| 6146447 | Sircar et al. | Nov 2000 | A |
| 6152134 | Webber et al. | Nov 2000 | A |
| 6156101 | Naheiri | Dec 2000 | A |
| 6162283 | Conrad et al. | Dec 2000 | A |
| 6171371 | Derive et al. | Jan 2001 | B1 |
| 6176897 | Keefer | Jan 2001 | B1 |
| 6183538 | Naheiri | Feb 2001 | B1 |
| 6212904 | Arkharov et al. | Apr 2001 | B1 |
| 6217635 | Conrad et al. | Apr 2001 | B1 |
| 6287366 | Derive et al. | Sep 2001 | B1 |
| 6290759 | Fenner et al. | Sep 2001 | B1 |
| 6302107 | Richer, II et al. | Oct 2001 | B1 |
| 6311719 | Hill et al. | Nov 2001 | B1 |
| 6314957 | Boissin et al. | Nov 2001 | B1 |
| 6344069 | Smolarek et al. | Feb 2002 | B2 |
| 6346139 | Czabala | Feb 2002 | B1 |
| 6372026 | Takemasa et al. | Apr 2002 | B1 |
| 6425938 | Xu et al. | Jul 2002 | B1 |
| 6428607 | Xu et al. | Aug 2002 | B1 |
| 6432170 | Chiang et al. | Aug 2002 | B1 |
| 6446630 | Todd, Jr. | Sep 2002 | B1 |
| 6457485 | Hill et al. | Oct 2002 | B2 |
| 6461410 | Abe et al. | Oct 2002 | B1 |
| 6468328 | Sircar et al. | Oct 2002 | B2 |
| 6471744 | Hill | Oct 2002 | B1 |
| 6478850 | Warren | Nov 2002 | B1 |
| 6478857 | Czabala | Nov 2002 | B2 |
| 6511526 | Jagger et al. | Jan 2003 | B2 |
| 6520176 | Dubois et al. | Feb 2003 | B1 |
| 6521143 | Genkin et al. | Feb 2003 | B1 |
| 6524370 | Maheshwary et al. | Feb 2003 | B2 |
| 6544318 | Dee et al. | Apr 2003 | B2 |
| 6547851 | Warren | Apr 2003 | B2 |
| 6551384 | Ackley et al. | Apr 2003 | B1 |
| 6572688 | Irven et al. | Jun 2003 | B2 |
| 6576043 | Zwilling et al. | Jun 2003 | B2 |
| 6585804 | Kleinberg et al. | Jul 2003 | B2 |
| 6605136 | Graham et al. | Aug 2003 | B1 |
| 6629525 | Hill et al. | Oct 2003 | B2 |
| 6641644 | Jagger et al. | Nov 2003 | B2 |
| 6641645 | Lee et al. | Nov 2003 | B1 |
| 6651653 | Honkonen et al. | Nov 2003 | B1 |
| 6651658 | Hill et al. | Nov 2003 | B1 |
| 6658894 | Golden et al. | Dec 2003 | B2 |
| 6687164 | Honkonen et al. | Jan 2004 | B2 |
| 6691702 | Appel et al. | Feb 2004 | B2 |
| 6698423 | Honkonen et al. | Mar 2004 | B1 |
| 6712087 | Hill et al. | Mar 2004 | B2 |
| 6712886 | Kim | Mar 2004 | B2 |
| 6764534 | McCombs et al. | Jul 2004 | B2 |
| 6793719 | Kim et al. | Sep 2004 | B2 |
| 6802889 | Graham et al. | Oct 2004 | B2 |
| 6805729 | Lim et al. | Oct 2004 | B2 |
| 6811590 | Lee et al. | Nov 2004 | B2 |
| 6824590 | Dee et al. | Nov 2004 | B2 |
| 6866041 | Hardy, Jr. et al. | Mar 2005 | B2 |
| 6866950 | Connor et al. | Mar 2005 | B2 |
| 6878186 | Neary | Apr 2005 | B2 |
| 6908503 | McCombs et al. | Jun 2005 | B2 |
| 6935460 | McCombs et al. | Aug 2005 | B2 |
| D510169 | Deane et al. | Sep 2005 | S |
| 6949133 | McCombs et al. | Sep 2005 | B2 |
| 6953498 | Walker et al. | Oct 2005 | B2 |
| 6959728 | McCombs et al. | Nov 2005 | B2 |
| 7011092 | McCombs et al. | Mar 2006 | B2 |
| 7011898 | Butt et al. | Mar 2006 | B2 |
| 7025329 | Winter | Apr 2006 | B2 |
| 7066985 | Deane et al. | Jun 2006 | B2 |
| 7066986 | Haben et al. | Jun 2006 | B2 |
| D528212 | Conway et al. | Sep 2006 | S |
| 7105038 | Lee et al. | Sep 2006 | B2 |
| 7135059 | Deane et al. | Nov 2006 | B2 |
| 7156903 | McCombs | Jan 2007 | B2 |
| 7171963 | Jagger et al. | Feb 2007 | B2 |
| 7273051 | Whitley et al. | Sep 2007 | B2 |
| 7279029 | Occhialini et al. | Oct 2007 | B2 |
| 7285154 | Karwacki, Jr. et al. | Oct 2007 | B2 |
| 7291271 | Galbraith | Nov 2007 | B2 |
| 7329304 | Bliss et al. | Feb 2008 | B2 |
| 7350521 | Whitley et al. | Apr 2008 | B2 |
| 7368005 | Bliss et al. | May 2008 | B2 |
| 7390350 | Weist, Jr. et al. | Jun 2008 | B2 |
| 7402193 | Bliss et al. | Jul 2008 | B2 |
| 7425231 | Carolan et al. | Sep 2008 | B2 |
| 7431032 | Jagger et al. | Oct 2008 | B2 |
| 7438745 | Deane et al. | Oct 2008 | B2 |
| 7445663 | Hunter et al. | Nov 2008 | B1 |
| 7452407 | Golden et al. | Nov 2008 | B2 |
| 7455717 | Sprinkle | Nov 2008 | B2 |
| 7473299 | Occhialini et al. | Jan 2009 | B2 |
| 7491040 | McCombs et al. | Feb 2009 | B2 |
| 7500490 | Wagner | Mar 2009 | B2 |
| 7510601 | Whiley et al. | Mar 2009 | B2 |
| 7517385 | Winter | Apr 2009 | B2 |
| 7533872 | Lee et al. | May 2009 | B2 |
| 7585351 | Deane et al. | Sep 2009 | B2 |
| 7604004 | Jagger et al. | Oct 2009 | B2 |
| 7604005 | Jagger et al. | Oct 2009 | B2 |
| 7651549 | Whitley | Jan 2010 | B2 |
| 7686870 | Deane et al. | Mar 2010 | B1 |
| 7708802 | Deane et al. | May 2010 | B1 |
| 7713421 | Galbraith | May 2010 | B2 |
| 7717981 | LaBuda et al. | May 2010 | B2 |
| 7722698 | Thompson et al. | May 2010 | B2 |
| 7722700 | Sprinkle | May 2010 | B2 |
| 7730887 | Deane et al. | Jun 2010 | B2 |
| 7753996 | Deane et al. | Jul 2010 | B1 |
| 7758672 | Lee et al. | Jul 2010 | B2 |
| 7766010 | Jagger et al. | Aug 2010 | B2 |
| 7771519 | Carolan et al. | Aug 2010 | B2 |
| 7780768 | Taylor et al. | Aug 2010 | B2 |
| 7794522 | Bliss et al. | Sep 2010 | B2 |
| 7841343 | Deane et al. | Nov 2010 | B2 |
| 7857894 | Taylor et al. | Dec 2010 | B2 |
| 7866315 | Jagger et al. | Jan 2011 | B2 |
| 7879138 | Lee et al. | Feb 2011 | B2 |
| 7922789 | Deane et al. | Apr 2011 | B1 |
| 7947118 | Rarig et al. | May 2011 | B2 |
| 3016918 | LaBuda et al. | Sep 2011 | A1 |
| 8142544 | Taylor et al. | Mar 2012 | B2 |
| 8148583 | Underwood et al. | Apr 2012 | B2 |
| 8262783 | Stoner et al. | Sep 2012 | B2 |
| 8303683 | Boulet et al. | Nov 2012 | B2 |
| 3377181 | Taylor et al. | Feb 2013 | A1 |
| 8366815 | Taylor et al. | Feb 2013 | B2 |
| 3440004 | Taylor et al. | May 2013 | A1 |
| 8529674 | Lee et al. | Sep 2013 | B2 |
| 8568519 | Taylor et al. | Oct 2013 | B2 |
| 8580015 | Taylor et al. | Nov 2013 | B2 |
| 8603220 | Rarig et al. | Dec 2013 | B2 |
| D700701 | Taylor et al. | Mar 2014 | S |
| 8702841 | Taylor et al. | Apr 2014 | B2 |
| D706211 | Taylor et al. | Jun 2014 | S |
| 8753426 | Zheng et al. | Jun 2014 | B2 |
| 8858689 | Stoner et al. | Oct 2014 | B2 |
| 9101872 | Rarig et al. | Aug 2015 | B2 |
| 9199190 | Malik et al. | Dec 2015 | B2 |
| 9220864 | Taylor et al. | Dec 2015 | B2 |
| D749220 | Taylor et al. | Feb 2016 | S |
| 9283346 | Taylor et al. | Mar 2016 | B2 |
| D770608 | Allum et al. | Nov 2016 | S |
| 9592360 | Taylor et al. | Mar 2017 | B2 |
| 9669349 | Lau et al. | Jun 2017 | B1 |
| 9731241 | Kalbassi et al. | Aug 2017 | B2 |
| 9907926 | Allum | Mar 2018 | B2 |
| 9925514 | Coe et al. | Mar 2018 | B2 |
| 9995645 | Allum | Jun 2018 | B2 |
| D851767 | Allum et al. | Jun 2019 | S |
| 10343139 | Bhadra et al. | Jul 2019 | B2 |
| 10384028 | Allum et al. | Aug 2019 | B2 |
| D860459 | Burgess et al. | Sep 2019 | S |
| 10478770 | Sanderson et al. | Nov 2019 | B2 |
| D876615 | Allum et al. | Feb 2020 | S |
| 10576455 | Weist, Jr. et al. | Mar 2020 | B2 |
| 20030005928 | Appel et al. | Jan 2003 | A1 |
| 20030106430 | Dee et al. | Jun 2003 | A1 |
| 20030167924 | McCombs et al. | Sep 2003 | A1 |
| 20040103894 | Loncar | Jun 2004 | A1 |
| 20050072298 | Deane et al. | Apr 2005 | A1 |
| 20050072306 | Deane et al. | Apr 2005 | A1 |
| 20050072423 | Deane et al. | Apr 2005 | A1 |
| 20050072426 | Deane et al. | Apr 2005 | A1 |
| 20050103341 | Deane et al. | May 2005 | A1 |
| 20050257686 | Occhialini et al. | Nov 2005 | A1 |
| 20050274381 | Deane et al. | Dec 2005 | A1 |
| 20060090759 | Howes et al. | May 2006 | A1 |
| 20060124128 | Deane et al. | Jun 2006 | A1 |
| 20060174871 | Jagger et al. | Aug 2006 | A1 |
| 20060174875 | Jagger et al. | Aug 2006 | A1 |
| 20060174877 | Jagger et al. | Aug 2006 | A1 |
| 20060174880 | Jagger et al. | Aug 2006 | A1 |
| 20060174881 | Jagger et al. | Aug 2006 | A1 |
| 20060230924 | Deane et al. | Oct 2006 | A1 |
| 20060230928 | Seaton | Oct 2006 | A1 |
| 20060283325 | Sugano | Dec 2006 | A1 |
| 20060292654 | Reardon | Dec 2006 | A1 |
| 20070056583 | Jagger et al. | Mar 2007 | A1 |
| 20070056584 | Jagger et al. | Mar 2007 | A1 |
| 20070289446 | Occhialini et al. | Dec 2007 | A1 |
| 20080000353 | Rarig et al. | Jan 2008 | A1 |
| 20080072907 | Deane et al. | Mar 2008 | A1 |
| 20080105258 | Deane et al. | May 2008 | A1 |
| 20080110338 | Taylor et al. | May 2008 | A1 |
| 20080168901 | Carolan et al. | Jul 2008 | A1 |
| 20080202337 | Taylor et al. | Aug 2008 | A1 |
| 20080282883 | Rarig et al. | Nov 2008 | A1 |
| 20090071333 | LaBuda et al. | Mar 2009 | A1 |
| 20090126736 | Taylor et al. | May 2009 | A1 |
| 20090131763 | Taylor et al. | May 2009 | A1 |
| 20100282084 | Taylor et al. | Nov 2010 | A1 |
| 20100294133 | Lee et al. | Nov 2010 | A1 |
| 20110023712 | Rarig et al. | Feb 2011 | A1 |
| 20110067566 | Taylor et al. | Mar 2011 | A1 |
| 20110271833 | Tentarelli et al. | Nov 2011 | A1 |
| 20110275866 | Underwood et al. | Nov 2011 | A1 |
| 20120167883 | Taylor et al. | Jul 2012 | A1 |
| 20120167886 | Taylor et al. | Jul 2012 | A1 |
| 20120167887 | Taylor et al. | Jul 2012 | A1 |
| 20120167888 | Taylor et al. | Jul 2012 | A1 |
| 20120266883 | Taylor et al. | Oct 2012 | A1 |
| 20130019752 | Stoner et al. | Jan 2013 | A1 |
| 20130269519 | Taylor et al. | Oct 2013 | A1 |
| 20130299023 | Rarig et al. | Nov 2013 | A1 |
| 20130305929 | Malik et al. | Nov 2013 | A1 |
| 20140033918 | Zheng et al. | Feb 2014 | A1 |
| 20140137741 | Taylor et al. | May 2014 | A1 |
| 20140353886 | Thayer et al. | Dec 2014 | A1 |
| 20150107585 | Allum | Apr 2015 | A1 |
| 20150107592 | Allum | Apr 2015 | A1 |
| 20150182720 | Taylor et al. | Jul 2015 | A1 |
| 20150250973 | Allum et al. | Sep 2015 | A1 |
| 20150360167 | Kalbassi et al. | Dec 2015 | A1 |
| 20160022950 | Taylor et al. | Jan 2016 | A1 |
| 20170113013 | Allum | Apr 2017 | A1 |
| 20170143926 | Allum et al. | May 2017 | A1 |
| 20170239640 | Coe et al. | Aug 2017 | A1 |
| 20170239641 | Coe et al. | Aug 2017 | A1 |
| 20170340851 | Allum et al. | Nov 2017 | A1 |
| 20170348501 | Taylor et al. | Dec 2017 | A1 |
| 20170361052 | Taylor et al. | Dec 2017 | A1 |
| 20180001048 | Allum | Jan 2018 | A1 |
| 20180200474 | Allum et al. | Jul 2018 | A1 |
| 20180200475 | Allum et al. | Jul 2018 | A1 |
| 20180364119 | Allum | Dec 2018 | A1 |
| 20190091651 | Bhadra et al. | Mar 2019 | A1 |
| 20190175860 | Allum et al. | Jun 2019 | A1 |
| 20190193018 | Sanderson et al. | Jun 2019 | A1 |
| 20190201835 | Sanderson et al. | Jul 2019 | A1 |
| 20190291078 | Weist, Jr. et al. | Sep 2019 | A1 |
| 20200054986 | Whitley et al. | Feb 2020 | A1 |
| 20200054987 | Bhadra et al. | Feb 2020 | A1 |
| 20200054988 | Wagner et al. | Feb 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 368649 | May 1990 | EP |
| 760247 | Mar 1997 | EP |
| 860646 | Aug 1998 | EP |
| 0873776 | Oct 1998 | EP |
| 1125623 | Aug 2001 | EP |
| 2174922 | Nov 1986 | GB |
| 9857727 | Dec 1998 | WO |
| 9858219 | Dec 1998 | WO |
| 9943416 | Sep 1999 | WO |
| 9943418 | Sep 1999 | WO |
| 3092817 | Nov 2003 | WO |
| Entry |
|---|
| US 10,265,491 B2, 04/2019, Allum et al. (withdrawn) |
| Recommendations of the Fifth Oxygen Consensus Conference, 1999. |
| “AirSep lowers boom”, www.hmenews.com/2004.12/depts/vendors/vendors1.htm, 2004. |
| Peter L Bliss, Robert W Mccoy, Alexander B Adams, A Bench Study Comparison of Demand Oxygen Delivery Systems and Continuous Flow Oxygen, Respiratory Care, Aug. 1999, vol. 44. No 8. |
| Inter Partes Reexamination Certificate (1210th) U.S. Pat. No. 7,841,343 C1, issued Dec. 7, 2015, Title: Systems and Methods for Delivering Therapeutic Gas to Patients, Inventor: Deane et al. Assignee: Inogen, Inc. Reexamination Request No. 95/001,885, filed Mar. 1, 2012. |
| Inter Partes Reexamination Certificate (1358th) U.S. Pat. No. 6,605,136 C1, issued Oct. 28, 2016, Title: Pressure Swing Adsorption Process Operation and Optimization, Inventor: Graham et al. Assignee: Inogen, Inc. Reexamination Request No. 95/001,886, filed May 2, 2012. |
| Number | Date | Country | |
|---|---|---|---|
| 20200269004 A1 | Aug 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14193504 | Feb 2014 | US |
| Child | 15931716 | US | |
| Parent | 13795977 | Mar 2013 | US |
| Child | 14193504 | US | |
| Parent | 13096362 | Apr 2011 | US |
| Child | 13795977 | US | |
| Parent | 11054341 | Feb 2005 | US |
| Child | 13096362 | US |
